GERD, Esophagitis, and Barrett’s Esophagus — Clinical Documentation Guide (2026)

🔍 Definition

Gastroesophageal Reflux Disease (GERD) is a chronic digestive condition in which stomach acid and/or bile flows back (refluxes) into the esophagus, causing irritation and symptoms. GERD is defined clinically as reflux sufficient to cause troublesome symptoms or complications, per the Montreal Definition (2006), which remains the foundational framework adopted by the American College of Gastroenterology (ACG).

Reflux Esophagitis is inflammation of the esophageal mucosa caused by prolonged acid exposure — the endoscopic/histologic finding that distinguishes GERD with esophagitis (K21.00/K21.01) from GERD without esophagitis (K21.9). The Los Angeles (LA) Classification grades reflux esophagitis A through D based on mucosal break extent.

Barrett’s Esophagus is a metaplastic change in which the normal stratified squamous epithelium of the distal esophagus is replaced by columnar intestinal-type epithelium, a premalignant condition that develops in 10–15% of patients with chronic GERD. The American Gastroenterological Association (AGA) and ACG recognize Barrett’s esophagus as the primary precursor to esophageal adenocarcinoma.

🗂️ Alternative Terminology

Clinicians, patients, and coders use varied terminology for these conditions. Understanding equivalences prevents under-coding and query opportunities.

🩺 Signs & Symptoms

GERD and esophagitis present with a range of esophageal (typical) and extra-esophageal (atypical) symptoms. Barrett’s esophagus is often asymptomatic, identified on surveillance endoscopy in GERD patients.

• Typical/esophageal: Heartburn (pyrosis) — burning sensation rising from epigastrium to chest; regurgitation — effortless return of gastric contents; dysphagia (with stricture or motility disorder); odynophagia (painful swallowing, more common with severe esophagitis); water brash; belching; nausea
• Atypical/extra-esophageal: Chronic cough; hoarseness/laryngitis; asthma or worsened bronchospasm; globus pharyngeus; dental erosion; chronic sinusitis; non-cardiac chest pain
• Alarm symptoms (require urgent evaluation): Dysphagia, odynophagia, unintentional weight loss, hematemesis/melena, anemia — may indicate malignancy or ulceration; see also ACG GERD Guidelines
• Barrett’s esophagus: Often clinically silent; typically discovered during EGD performed for GERD evaluation; patients at highest risk include white males ≥50 years with longstanding GERD, obesity, or tobacco use

Severity grading via Los Angeles Classification: Grade A (one or more mucosal breaks ≤5 mm) → Grade B (mucosal breaks >5 mm, not continuous between mucosal folds) → Grade C (mucosal breaks continuous between ≥2 mucosal folds but <75% of esophageal circumference) → Grade D (≥75% circumference).

🧭 Differential Diagnosis

Multiple conditions can mimic GERD or esophagitis; accurate documentation is essential to support the correct ICD-10-CM code.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators should prompt the coder or CDI specialist to review documentation for specificity and query opportunities:

🦴 Anatomy & Pathophysiology

The esophagus is a muscular tube approximately 25 cm in length, extending from the pharynx to the stomach through the diaphragm. Key anatomical structures in GERD pathophysiology:

• Lower esophageal sphincter (LES): The primary anti-reflux barrier — a tonically contracted smooth muscle segment at the gastroesophageal junction (GEJ). In GERD, LES tone is reduced or transient LES relaxations (TLESRs) are excessive, allowing acid egress. The pathophysiology of TLESRs is mediated via the vagus nerve and cholecystokinin.
• Hiatal hernia: Displacement of the gastric cardia above the diaphragm disrupts the LES-diaphragmatic pinchcock mechanism, a major anatomic contributor to GERD.
• Esophageal mucosal defense: Pre-epithelial (mucus, bicarbonate), epithelial (tight junctions, intracellular buffers), and post-epithelial (blood flow) layers protect against acid injury. Prolonged acid exposure overwhelms these defenses, producing inflammation (esophagitis).
• Metaplastic transformation (Barrett’s): Chronic acid (and bile) exposure induces transcriptional reprogramming of stem cells near the squamocolumnar junction (SCJ/Z-line). The resulting columnar intestinal metaplasia expresses CDX2 and MUC2 markers. The progression sequence is: GERD → Barrett’s → low-grade dysplasia → high-grade dysplasia → esophageal adenocarcinoma (EAC).
• Eosinophilic esophagitis (EoE) mechanism: Antigen-driven Th2 immune response causing eosinophil recruitment. Key mediators include eotaxin-3, IL-5, and IL-13. Distinct from GERD; coded separately as K20.0.

From a MS-DRG perspective, patients hospitalized for complications of GERD/esophagitis (e.g., GI hemorrhage, aspiration pneumonia) are grouped to DRGs 377–384 (GI hemorrhage) or 177–179 (respiratory with MCC/CC), significantly impacting reimbursement relative to ambulatory GERD management.

💊 Medication Impact / Treatment

Pharmacologic management of GERD and its complications is among the most common drug regimens in primary care and gastroenterology. Documenting the specific agents, dosing, and response is critical for CDI and coding accuracy.

• Proton pump inhibitors (PPIs): First-line therapy for GERD, reflux esophagitis, and Barrett’s esophagus management. Standard agents include omeprazole, esomeprazole (Nexium), pantoprazole (Protonix), lansoprazole, dexlansoprazole (Dexilant), rabeprazole. Oral PPIs are dispensed under Medicare Part D. IV pantoprazole (Protonix IV) — billed HCPCS J2930 for inpatient use. The presence of PPI therapy in the medication list supports GERD documentation but does not substitute for provider diagnosis.
• H2 receptor antagonists (H2RAs): Famotidine, cimetidine — used for mild GERD or maintenance; Step-down from PPIs; less effective for esophagitis healing.
• Antacids / Alginates: Symptomatic relief only; OTC (Tums, Maalox, Gaviscon); not separately coded or billed under Medicare Part B.
• Potassium-competitive acid blockers (P-CABs): Vonoprazan (Voquezna) — approved by FDA in 2023; emerging alternative to PPIs; faster onset; Part D covered.
• Prokinetics: Metoclopramide — may improve LES tone and gastric emptying in select GERD patients; associated with tardive dyskinesia risk with long-term use.
• Sucralfate: Mucosal protective agent; used adjunctively in esophagitis or pill esophagitis.
• Biologic therapy for EoE: Dupilumab (Dupixent) — FDA-approved for EoE (K20.0); IL-4/IL-13 antagonist; injectable; Medicare Part B if provider-administered; Part D if self-injected.

Medication-related coding implications: Long-term PPI use may warrant coding of Z79.899 (other long-term drug therapy) when clinically relevant. Aspirin or NSAID use contributing to esophageal injury can be captured with additional Z codes.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following official ICD-10-CM Official Guidelines for Coding and Reporting (FY2026) and Tabular List instructions apply to GERD, esophagitis, and Barrett’s esophagus coding.

Category K21 — Gastro-esophageal Reflux Disease

• Category K21 has an Excludes1 for newborn esophageal reflux (P78.83) — do not assign K21.x for pediatric reflux coded as neonatal.
• K21.0 (GERD with esophagitis) is a non-billable parent code; use K21.00 (without bleeding) or K21.01 (with bleeding) as the specific code. “Reflux esophagitis” and “erosive esophagitis” index to K21.0x.
• K21.9 is the code for GERD without esophagitis and is appropriate when endoscopy is negative or not performed and provider documents GERD symptomatically.
• Sequencing: When GERD with esophagitis is the reason for an encounter, K21.00 or K21.01 is principal/first-listed. If esophagitis is a complication of another condition (e.g., Zollinger-Ellison syndrome E16.4), sequence the underlying condition first per guideline I.C.11.

Category K20 — Esophagitis

• K20 has an Excludes1 list: erosion of esophagus (K22.1–), esophagitis with gastro-esophageal reflux disease (K21.0–), reflux esophagitis (K21.0–), and ulcerative esophagitis (K22.1–). This means K20.x and K21.0x are mutually exclusive — when GERD causes the esophagitis, use K21.00/K21.01, not K20.x.
• K20.0 (Eosinophilic esophagitis) has an Excludes2 for eosinophilic gastritis or gastroenteritis (K52.81), which may be coded together.
• K20.80 (Other esophagitis without bleeding) and K20.81 (with bleeding) cover infectious, chemical, radiation, and other non-reflux, non-eosinophilic esophagitis.
• K20.90/K20.91 (Esophagitis unspecified) should be avoided when etiology is known; query the provider for specificity.

Category K22.7 — Barrett’s Esophagus

• Barrett’s esophagus has an Excludes1 for Barrett’s ulcer (K22.1–) and malignant neoplasm of esophagus (C15.–). When esophageal adenocarcinoma develops from Barrett’s, assign C15.x — do not code K22.7x concurrently with C15.x per Excludes1 instruction.
• Always assign the most specific 5th-character code: K22.70 (no dysplasia), K22.710 (low-grade), K22.711 (high-grade), K22.719 (dysplasia unspecified). The parent K22.7 and K22.71 are non-billable.
• When Barrett’s esophagus coexists with GERD, code both K21.x and K22.7x — there is no Excludes note precluding dual coding. GERD typically sequences first unless Barrett’s management is the primary focus of the encounter.
• Dysplasia grading must be supported by pathology report; query the provider if the note states “Barrett’s with dysplasia” without specifying grade (prompts K22.719 or query for K22.710 vs. K22.711).

Additional Guideline Considerations

• Hiatal hernia (K44.x): Code separately when documented; often coexists with GERD. A sliding hiatal hernia is K44.9 (without obstruction/gangrene), K44.0 (with obstruction). Sequence GERD or hernia first depending on the reason for the encounter.
• Aspiration pneumonia (J69.0): When GERD leads to aspiration events, J69.0 codes separately. Code the underlying cause (reflux, aspiration during procedure) as instructed by the Tabular. J69.0 maps to HCC 280 in v28 — a significant risk-adjustment consideration.
• Outpatient coding: Per Guideline IV.H, code confirmed conditions documented by the provider; do not code “rule out” or “probable” diagnoses in outpatient settings.
• Inpatient coding: Per Guideline II, “uncertain” diagnoses (probable, suspected, possible) may be coded as if confirmed if still present at discharge. This is particularly relevant for Barrett’s with suspected vs. confirmed dysplasia.

🔢 ICD-10-CM Code Set (FY2026)

All codes verified for FY2026 (effective October 1, 2025) per the CMS ICD-10-CM FY2026 code files and NCHS ICD-10-CM tabular.

🔎 Indexing

The following Alphabetic Index entries guide code selection for GERD, esophagitis, and Barrett’s esophagus. Coders should verify all index leads in the Tabular List per Official Guidelines.

🏥 CPT (2026)

The following AMA CPT 2026 procedure codes are commonly used for the evaluation and management of GERD, esophagitis, and Barrett’s esophagus. All EGD codes in the 43235–43270 series are “transoral, flexible” procedures.

🧾 HCPCS (2026)

The following HCPCS Level II codes are relevant to GERD and esophageal disorder management. Most oral PPI formulations are covered under Medicare Part D, not Part B.

Note: The majority of PPI medications used in GERD management are oral and dispensed at retail/mail-order pharmacies under Medicare Part D. They are not separately reportable as HCPCS Part B codes in the outpatient or physician setting. IV proton pump inhibitor therapy (e.g., pantoprazole IV J2930) is billable under Part B when administered in a covered setting for a covered indication such as acute GI hemorrhage.

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic for ICD-10-CM/PCS advisories are relevant to GERD, esophagitis, and Barrett’s esophagus. Coding Clinic guidance is authoritative for ICD-10-CM/PCS questions and should be consulted when coding these conditions.

Note: Access to specific Coding Clinic volume/issue references requires an AHA Coding Clinic subscription. The guidance summarized above reflects published AHA Coding Clinic positions applicable to FY2026 coding.

💰 HCC / Risk Adjustment (v28)

Under CMS-HCC Model v28 (fully operative for payment year 2026), the vast majority of GERD, reflux esophagitis, and Barrett’s esophagus codes do not map to a risk-adjusting HCC. However, their complications and sequelae do — making specificity documentation critically important for CDI.

CDI Value Without HCC: Even though GERD and Barrett’s do not carry HCC weight, comprehensive and specific documentation serves multiple purposes: (1) HEDIS/STAR quality measures; (2) Audit defensibility for PPIs and endoscopy frequency; (3) Accurate MS-DRG assignment when these conditions are MCC/CC-equivalent for inpatient stays; (4) Population health registries for Barrett’s surveillance programs; (5) Risk stratification for esophageal cancer screening.

✍️ CDI Query Templates

All query templates below comply with ACDIS/AHIMA Compliant Query Practice Guidelines — non-leading, multiple-choice or open-ended, clinical evidence-based, and documented in the medical record.

🧑‍⚕️ Treatments (Clinical)

Clinical management of GERD, esophagitis, and Barrett’s esophagus spans lifestyle modification, pharmacologic therapy, and endoscopic/surgical intervention — all relevant to coding and CDI documentation.

Lifestyle and Behavioral Modifications

• Weight reduction in obese patients — most impactful non-pharmacologic intervention per ACG GERD Guidelines
• Head-of-bed elevation 6–8 inches (nocturnal GERD)
• Dietary trigger avoidance (caffeine, alcohol, fatty foods, citrus, chocolate, mint)
• Smoking cessation (tobacco reduces LES pressure)
• Avoid eating within 2–3 hours of bedtime

Pharmacologic Therapy

• Step-up therapy: Antacids/H2RA → standard-dose PPI → high-dose PPI → add-on therapy
• Step-down therapy: Start with full-dose PPI for healing esophagitis, then step down to maintenance lowest effective dose
• PPI optimization: Prescribe 30–60 minutes before meal for maximum efficacy; once-daily dosing usually sufficient for K21.00; twice-daily for LA Grade C/D or refractory disease
• H. pylori testing: Test and treat H. pylori if identified, especially with peptic features; use Z79.899 for ongoing therapy when appropriate

Endoscopic Treatments

• Radiofrequency ablation (RFA/HALO): Standard of care for Barrett’s with dysplasia; CPT 43257; achieves 80–90% complete eradication of intestinal metaplasia per AGA Barrett’s Guidelines
• Cryotherapy: Liquid nitrogen or CO₂ spray cryoablation; CPT 43270; used for RFA failures or nodular Barrett’s
• Endoscopic mucosal resection (EMR): CPT 43254; for nodular HGD or early adenocarcinoma ≤2 cm; provides pathologic staging specimen
• Esophageal dilation: CPT 43249 for peptic stricture; typically performed with EGD
• Transoral fundoplication (TIF/EsophyX): Endoscopic anti-reflux procedure; CPT 43210; emerging alternative to Nissen fundoplication

Surgical Treatments

• Laparoscopic Nissen fundoplication: 360° wrap of stomach fundus around LES; definitive surgical anti-reflux procedure; CPT 43280 (laparoscopic), 43327 (open)
• Partial fundoplication (Toupet, Dor): 270° wrap; lower dysphagia rate; preferred in patients with esophageal dysmotility
• LINX magnetic sphincter augmentation: Magnetic bead device placed around LES; CPT 43284 (laparoscopic); growing evidence base; less invasive than fundoplication
• POEM (Per-oral endoscopic myotomy): CPT 43497; primary treatment for achalasia (K22.0); occasionally considered for GERD-complicating spasm
• Esophagectomy: CPT 43107–43124 range; reserved for high-grade dysplasia not amenable to endoscopic therapy, or adenocarcinoma (C15.x)

🎓 Patient Education / Summary

This section summarizes key patient education points relevant to GERD, esophagitis, and Barrett’s esophagus — useful for CDI specialists preparing patient-facing materials and for coders understanding the clinical context of documented conditions.

What is GERD?

GERD is a condition where stomach acid repeatedly flows back into the esophagus (the tube connecting your mouth and stomach), irritating the lining. It is one of the most common digestive conditions in the United States, affecting an estimated 20% of adults. Most people experience heartburn as the main symptom — a burning feeling in the chest that often worsens after eating or when lying down. For more information, see NIDDK: Acid Reflux in Adults.

What is Barrett’s Esophagus?

In some people with long-standing GERD, the normal lining of the lower esophagus changes to a different type of tissue (called intestinal metaplasia or columnar epithelium). This change is called Barrett’s esophagus. Barrett’s esophagus is a premalignant condition — meaning it increases the risk of a type of cancer called esophageal adenocarcinoma. Regular endoscopic surveillance is recommended to monitor for changes (dysplasia). See NIDDK: Barrett’s Esophagus.

When Should Patients Seek Urgent Care?

• Difficulty swallowing (dysphagia) or painful swallowing (odynophagia)
• Vomiting blood or material that looks like coffee grounds
• Black or tarry stools (melena)
• Unintentional weight loss
• Chest pain (always rule out cardiac cause first)
• These symptoms may indicate complications such as esophageal ulcer, stricture, or cancer — and require prompt medical evaluation

Key Coding/CDI Takeaways for Clinicians

• Specificity matters: Document whether GERD is accompanied by esophagitis; document esophagitis etiology (reflux, eosinophilic, infectious); document Barrett’s dysplasia grade from pathology.
• Bleeding status: Always note whether esophagitis or ulceration is accompanied by active or recent bleeding — affects ICD-10-CM code selection and MS-DRG assignment.
• Barrett’s surveillance: Document the surveillance interval recommendation and pathologic findings at each EGD; dysplasia grade determines code (K22.70 vs. K22.710 vs. K22.711) and treatment (surveillance vs. ablation).
• Complications: Document aspirations, strictures, and malignant transformation explicitly — these complications carry significant HCC and MS-DRG impact.
• Long-term PPI therapy: When PPI is used long-term (chronic GERD management), document the clinical indication and periodically reassess — supports Z79.899 and audit defensibility.

For further clinical guidance, see the ACG Clinical Guideline for GERD (2022), the AGA Clinical Practice Update on Barrett’s Esophagus, and the NCHS ICD-10-CM Official Tabular (FY2026).

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)